| Name | Brivudine |
| Description | Brivudine (BVDU), an antiviral medicine, is used in the therapy of herpes zoster. |
| In vitro | Brivudine is an analog of thymidine, and is incorporated into the viral DNA. It blocks the action of DNA polymerases thereby inhibiting viral replication. It has a stronger antiviral effect against the varicella-zoster virus than reference compounds such as aciclovir or penciclovir[1]. It has high, selective activity against varicella zoster virus (VZV), inhibiting VZV replication, possibly through competitive inhibition of viral DNA polymerase, or by acting as an alternative substrate to deoxythymidine triphosphate, causing viral DNA strand breakage[2]. |
| In vivo | At a dose of 125 mg once daily, brivudine has been shown to be superior to aciclovir with respect to reducing the period of new blister production and shortening the duration of post-herpetic neuralgia[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (150.09 mM), Sonication is recommended.
|
| Keywords | VZV | Inhibitor | inhibit | HSV-1 | Cytomegalovirus | CMV | Brivudine |
| Inhibitors Related | Floxuridine | Docusate sodium | Octyl gallate | 1-Docosanol | Oxytetracycline Hydrochloride | S-Methylisothiourea sulfate | Adenosine 5'-monophosphate monohydrate | Oxyresveratrol | Idoxuridine | Cytarabine | Acyclovir | Ganciclovir |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
